Twinbeech Capital LP I Mab Transaction History

Twinbeech Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $693 - $2,134	173 Added 1.36%	12,909 $52,000
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $105,326 - $234,724	12,736 New	12,736 $144,000
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $83,328 - $311,849	-6,645 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $300,885 - $495,052	6,645 New	6,645 $315,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.